Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2018

01-03-2018 | Current Opinion

Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol

Author: Thomas F. Whayne

Published in: Drugs | Issue 3/2018

Login to get access

Abstract

The clinical importance and benefit of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appears well established for the high-risk cardiovascular (CV) patient. This applies especially to the statin-intolerant patient or the patient who does not attain an appropriate low-density lipoprotein cholesterol (LDL-C) target. Therefore, the barriers to appropriate clinical use of the PCSK9 inhibitors involve cost and not the documented CV benefit or LDL-C lowering. Multiple roadblocks affect many high-risk CV patients in arranging approval of a PCSK9 inhibitor. Overcoming these roadblocks may require legal pressures, some increased regulation, and facilitation by competitive forces.
Literature
1.
Whayne TF Jr. Is there an ideal low-density lipoprotein cholesterol level? Confusion regarding lipid guidelines, low-density lipoprotein cholesterol targets, and medical management. Int J Angiol. 2017;26(2):73–7.CrossRefPubMed
2.
Whayne TF. Low-density lipoprotein cholesterol (LDL-C): how low? Curr Vasc Pharmacol. 2017;15:374–9.CrossRefPubMed
3.
Klose G. Introduction of PCSK9 inhibitors : new perspectives in treatment and practical implementation. Herz. 2016;41(4):307–12.CrossRefPubMed
4.
McDonagh M, Peterson K, Holzhammer B, Fazio S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641–53.CrossRefPubMed
5.
Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140–8.CrossRefPubMedPubMedCentral
6.
Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016;134(24):1931–43.CrossRefPubMedPubMedCentral
7.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.CrossRefPubMed
8.
9.
Bekkering GE, Kleijnen J. Procedures and methods of benefit assessments for medicines in Germany. Eur J Health Econ. 2008;9(Suppl 1):5–29.CrossRefPubMed
10.
Kreis J, Busse R. From evidence assessments to coverage decisions?: the case example of glinides in Germany. Health Policy. 2012;104(1):27–31.CrossRefPubMed
11.
Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics. 2002;20(9):577–91.CrossRefPubMed
12.
13.
Kumar B, Baldi A. The challenge of counterfeit drugs: a comprehensive review on prevalence, detection and preventive measures. Curr Drug Saf. 2016;11(2):112–20.CrossRefPubMed
14.
Kuehn BM. Coverage and cardioprotective benefits of PCSK9 take center stage at the American College of Cardiology meeting. Circulation. 2017;135(25):2562–3.CrossRefPubMed
15.
16.
17.
Nunan M, Duke T. Effectiveness of pharmacy interventions in improving availability of essential medicines at the primary healthcare level. Trop Med Int Health. 2011;16(5):647–58.CrossRefPubMed
18.
Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):128–44.CrossRefPubMed
19.
20.
Hillman BJ, Frank RA, Rodriguez GM, I Medical, Technology Alliance Workshop p. New pathways to medicare coverage for innovative PET radiopharmaceuticals: report of a medical imaging & technology alliance (MITA) workshop. J Nucl Med. 2012;53(2):336–42.CrossRefPubMed
21.
Hillman BJ, Frank RA, Rodriguez GM, Medical I, Technology Alliance Workshop P. New pathways to medicare coverage for innovative PET radiopharmaceuticals: report of a Medical Imaging & Technology Alliance (MITA) workshop. J Am Coll Radiol. 2012;9(2):108–14.CrossRefPubMed
22.
Lobban TC, Camm AJ. Patient associations as stakeholders: a valuable partner for facilitating access to therapy. Europace. 2011;13(Suppl 2):ii21–4.PubMed
23.
McCormick D, Sayah A, Lokko H, Woolhandler S, Nardin R. Access to care after Massachusetts’ health care reform: a safety net hospital patient survey. J Gen Intern Med. 2012;27(11):1548–54.CrossRefPubMedPubMedCentral
24.
Fay M, Malley J. HSA growth and the associated opportunities/challenges presented by pharmacy benefits. Benefits Q. 2014;30(3):8–15.PubMed
25.
Dong X, Fetterolf D. Specialty pharmacy: an emerging area of interest for medical management. Dis Manag. 2005;8(2):73–85.CrossRefPubMed
26.
Patterson CJ. Best practices in specialty pharmacy management. J Manag Care Pharm. 2013;19(1):42–8.PubMed
27.
Kesselheim AS, Tan YT, Darrow JJ, Avorn J. Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs. Health Aff (Millwood). 2014;33(10):1770–8.CrossRefPubMed
28.
Penington R, Stubbings JA. Evaluation of specialty drug price trends using data from retrospective pharmacy sales transactions. J Manag Care Spec Pharm. 2016;22(9):1010–7.CrossRefPubMed
29.
Lotvin AM, Shrank WH, Singh SC, Falit BP, Brennan TA. Specialty medications: traditional and novel tools can address rising spending on these costly drugs. Health Aff (Millwood). 2014;33(10):1736–44.CrossRefPubMed
30.
Kirschenbaum BE. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists. Am J Health Syst Pharm. 2009;66(24 Suppl 7):S13–20.CrossRefPubMed
31.
Patel BN, Audet PR. A review of approaches for the management of specialty pharmaceuticals in the United States. Pharmacoeconomics. 2014;32(11):1105–14.CrossRefPubMedPubMedCentral
32.
Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013;19(7):542–8.PubMed
33.
Starner CI, Alexander GC, Bowen K, Qiu Y, Wickersham PJ, Gleason PP. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums. Health Aff (Millwood). 2014;33(10):1761–9.CrossRefPubMed
34.
Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a medical injectable drug program. J Manag Care Pharm. 2011;17(1):51–9.PubMed
35.
Tu HT, Samuel DR. Limited options to manage specialty drug spending. Res Brief. 2012;22:1–13.
36.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.CrossRefPubMed
37.
Gomes VS, Amador TA. Studies published in indexed journals on lawsuits for medicines in Brazil: a systematic review. Cad Saude Publica. 2015;31(3):451–62.CrossRefPubMed
38.
Pettignano R, Caley SB, McLaren S. The health law partnership: adding a lawyer to the health care team reduces system costs and improves provider satisfaction. J Public Health Manag Pract. 2012;18(4):E1–3.CrossRefPubMed
Metadata
Title
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
Author
Thomas F. Whayne
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0867-9

Other articles of this Issue 3/2018

Drugs 3/2018 Go to the issue

Review Article

Prevention and Treatment of Chronic Postsurgical Pain: A Narrative Review

Adis Drug Evaluation

Eculizumab: A Review in Generalized Myasthenia Gravis

Review Article

Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults

Review Article

Efficacy and Safety of Tiotropium in Children and Adolescents

AdisInsight Report

Netarsudil Ophthalmic Solution 0.02%: First Global Approval

Adis Drug Evaluation

Landiolol: A Review in Tachyarrhythmias